Peptides

A synthetic peptide for use as a blocking control in assays to test for specificity of RHBG antibody, catalog no. 70R-7321

Please enquire for more information about H-2kb tetramer peptide - Q7 including the price, delivery time and more detailed product information at the technical inquiry form on this page

KD20 peptide is a lysine-aspartic acid peptide with 20 repeating units. KD20 peptide is used to stimulate CD4+ T cells in vitro and KD20 actions result in protection against abscesses induced by bacteria.

SARS-CoV-2 Spike RBD 513-520 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 513-520 peptide is useful for vaccine development and for structure-activity relationship studies
SARS-CoV-2 Spike (S) glycoprotein
Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.
With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane.
SARS-CoV-2 Spike RBD:
The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.
SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 513-520 (Biotin-LC) peptide

Portion of HCMV

SARS-CoV-2 Spike RBD 395-430 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 395-430 peptide is useful for vaccine development and for structure-activity relationship studies
SARS-CoV-2 Spike (S) glycoprotein
Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.
With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane.
SARS-CoV-2 Spike RBD:
The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.
SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 395-430 (Biotin-LC) peptide

Selective agonist of Nav1.1

Thiol-TAT peptide.

SARS-CoV-2 Spike RBD 319-335 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 319-335 peptide is useful for vaccine development and for structure-activity relationship studies
SARS-CoV-2 Spike (S) glycoprotein
Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.
With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane.
SARS-CoV-2 Spike RBD:
The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.
SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 319-335 (Biotin-LC) peptide

Kv4.2 activator and Kv1.3 blocker

Selective Nav1.7 blocker

TET 830/Tetanus Toxin (830-844) peptide – QYIKANSKFIGITEL

Nav1.5 channel activator

Ovalbumin 154-159, also nammed TNGIIR peptide, is a portion of interest of the egg white albumen.

Blocker of α1-adrenoreceptor

Blocker of mid-low- (M-LVA) and high-voltage-activated (HVA) insect calcium channel (Ca(v)) currents

RANTES (or Regulated upon Activation, Normal T-cell Expressed and Secreted), also known as CCL5 (Chemokine (CC chemokine ligand 5), is a protein classified as a chemotactic cytokine or chemokine.
Chemokines are small soluble proteins that act as molecular signals to induce cellular migration during inflammation.
RANTES is a member of the CC chemokine family and is involved in immunoregulatory and inflammatory processes.
RANTES is expressed in a lot of immune cells and acts as a potent chemoattractant for T-cells, basophils, eosinophils, monocytes and other cell types by playing a major role in recruiting leukocytes into inflammatory sites and to activate them. RANTES also induces proliferation and activation of certain natural killer cells.
RANTES synthesis is induced by TNF-alpha and IL-1 alpha, interacts with CCR3, CCR1 and CCR5 and activates some G-protein coupled receptors.
Many of the biological activities of RANTES (Ca2+ influx, chemotactic response, basophil activation, T-cell signaling) are observed between 40 and 8000 ng/mL.

SARS-CoV-2 Spike RBM 500-509 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). SARS-CoV-2 Spike RBM 500-509 peptide is useful for vaccine development and for structure-activity relationship studies
SARS-CoV-2 Spike (S) glycoprotein
Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.
With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane.
SARS-CoV-2 Spike RBM:
The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.
SB-PEPTIDE also offers SARS-CoV-2 Spike RBM 500-509 (Biotin-LC) peptide

SK2 channel blocker

Scrambled LL-37 has the same peptide sequence as LL-37 but loses helixforming property.
Scrambled LL-37 can be used as a negative control of LL-37 studies.

GLP-1 (Human, Rat, Mouse)-EIA Kit is a ready-to-use kit that contains a recombinant human GLP-1 peptide. This kit is designed for the quantitative measurement of GLP-1 in human serum or plasma by ELISA. It uses a polyclonal antibody to detect the protein and has no cross-reactivity with other pancreatic hormones. The assay can be used with rat and mouse samples as well.

Boc-Gly-Arg-Arg-AMC is a research tool that has a high purity and is used in cell biology, antibody production, ion channels, and protein interactions. It is an inhibitor of ion channels, which can be used for pharmacology to study the function of ion channels. Boc-Gly-Arg-Arg-AMC has also been shown to inhibit binding between the ligand and receptor.

MAL dPEG®6-Acid is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. MAL dPEG®6-Acid is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

Orexin-A (Human, 17-33) is a neuropeptide also known as hypocretin-1 and this product is available as a 0.1 mg vial. Orexin-A is primarily produced by a group of neurons located in the lateral hypothalamus of the brain, known as the orexinergic neurons.
Orexin-A is involved in regulating a variety of physiological functions, including the sleep-wake cycle, appetite, energy metabolism, and reward pathways. It acts as an agonist for two G protein-coupled receptors, known as orexin receptor 1 and orexin receptor 2.
Studies have shown that disruption of orexin signaling can lead to sleep disorders, obesity, and other metabolic disorders. Orexin-A has also been studied for its potential as a therapeutic target for the treatment of these disorders.

Arphamenine B is an enzyme inhibitor that inhibits metalloproteinases and serine proteases. It has been shown to be a potent osteoinductive agent in cell culture. Arphamenine B has also been found to have a depressant effect on the growth of cells in culture, with lysine residues as the probable site of action. Arphamenine B has also been shown to inhibit soybean trypsin, which is a serine protease enzyme.

Neuropeptide W-30 (Rat) is a peptide that belongs to the family of neuropeptides. It has been identified as an inhibitor of the ion channel TRPV1 and TRPA1, which are involved in pain perception. Neuropeptide W-30 (Rat) also inhibits the activation of phospholipase C, protein kinase C, and cAMP response element binding protein. Neuropeptide W-30 (Rat) is used as a research tool for studying protein interactions and for pharmacological studies.

Amino-dPEG®6-t-Butyl Ester is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. Amino-dPEG®6-t-Butyl Ester is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

Bis-dPEG®29-Acid is a PEG polymer categorised as homobifunctional PEG (X-PEG X). Used as a linker, bis-dPEG®29-Acid is used to attached PEG to proteins, peptides, oligonucleotides, nanoparticles and small molecules via pegylation, a bioconjugation technique.

Leu-pNA is a protein synthesis inhibitor that binds to the active site of the enzyme peptidyl prolyl cis-trans isomerase (PPIase). This inhibitor prevents the enzyme from catalyzing the conversion of proline residues in peptides to their cis or trans isomers. Leu-pNA has been shown to inhibit proteolytic enzymes such as soybean trypsin and activated proteases, and also has an inhibitory effect on polymerase chain reaction (PCR) enzyme activities. The binding of Leu-pNA to PPIase can be reversed by heating at 60°C for 20 minutes.

This product which is available as a 0.5mg vial is amino acids 1-31 of the 84 amino acid parathyroid hormone (PTH) and can be used as an adenylate cyclase and bone growth stimulating peptide.
PTH is a peptide hormone that is secreted from the parathyroid gland in the event of abnormal serum calcium levels and it ultimately regulates calcium and phosphate levels in the body. The PTH exerts its activity through binding to the G-protein coupled receptor type 1 PTH receptor, which activates adenylate cyclase or phospholipase C thus activating pathways involved in the mediation of bone resorption and bone formation. This product is suitable for life science applications.

Endothelin-1 is a peptide that acts as a vasoconstrictor and plays an important role in the regulation of blood pressure. Endothelin-1 is also an endogenous ligand for two G protein-coupled receptors, ETA and ETB. Interesting Endothelin-1 is the most abundant isoform and is expressed in endothelial cells of every blood vessel. It exerts its vasoconstrictor effects through binding to ETA receptors located on the smooth muscle. This product has disulfide bonds between Cys1-Cys15 and Cys3-Cys11, sourced from Porcine, Canine, Rat, Mouse and Bovine and is available as a 0.1mg vial.

GIP (Gastric Inhibitory Polypeptide) is a peptide hormone that belongs to the family of incretin hormones. GIP has been shown to have an insulinotropic effect, which is mediated by its activation of glucose-dependent insulin release from pancreatic β-cells. It also has effects on lipid metabolism and plays a role in the regulation of food intake. GIP is produced by K cells in the ileum and colon and released into the bloodstream following food intake. The binding of GIP to its receptors leads to inhibition of gastric acid secretion, stimulation of gallbladder contraction, increased blood flow to the stomach, relaxation of pyloric sphincter muscles, and inhibition of gastric motility. This product is highly pure (> 98%) with no detectable endotoxin or other microbial contamination.

m-dPEG®37-acid is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. m-dPEG®37-acid is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

A synthetic snake toxin sourced from the black mamba, Dendroaspis polylepis polylepis which can be applied as a L-type Ca2+ channel blocker. This product has disulfide bonds between Cys3-Cys22, Cys17-Cys39, Cys41-Cys52, and Cys53-Cys58 and is available as a 0.1mg vial.

m-dPEG®36-Azide (Azido-m-dPEG®36) is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. m-dPEG®36-Azide (Azido-m-dPEG®36) is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

CCK-Octapeptide (26-33) is a peptide that is a member of the cholecystokinin family of peptides. CCK-Octapeptide (26-33) is an activator of the CCK receptor and can be used for research purposes. This peptide has been shown to inhibit ion channels, which are proteins that regulate the flow of ions across cell membranes, and may be used as a pharmacological tool or research tool.

Lys-Ala-AMC is an activator of ion channels and a ligand for receptors. It is used in research as a tool to study protein interactions, receptor pharmacology, and ion channel pharmacology. Lys-Ala-AMC binds to the α-subunit of voltage gated calcium channels and can activate these channels by increasing the rate of opening. This peptide also inhibits receptor binding by competing with the natural ligand. It has been shown to be an antagonist at the NMDA receptor and can inhibit the binding of glycine to this receptor.

m-dPEG®4-Azide (Azido-m-dPEG®4) is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. m-dPEG®4-Azide (Azido-m-dPEG®4) is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

CoV-2 IgG S1 antibody binds to both SARS-CoV and SARS-CoV-2 (COVID-19) with high affinity at amino acids 318-510 in the S1 domain of the Spike protein and can be used in ELISA assays. SARS Coronavirus is an enveloped virus containing three outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing antibodies. It has recently been shown that SARS is caused by a human coronavirus. Human coronaviruses are the major cause of upper respiratory tract illness in humans, such as the common cold. Coronaviruses are positive-stranded RNA viruses, featuring the largest viral RNA genomes known to date (27-31 kb). The first step in coronavirus infection is binding of the viral spike protein, a 139-kDa protein, to certain receptors on host cells. The spike protein is the main surface antigen of the coronavirus. The most prominent protein in the culture supernatants infected with SARS virus is a 46 kDa nucleocapsid protein. This suggests that the nucleocapsid protein is a major immunogen that may be useful for early diagnostics.
Recombinant Anti Human SARS CoV-2 IgG1 Kappa Spike S1 is a recombinant monoclonal antibody derived from HEL293 cells, which recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein. CoV-2 IgG S1 Antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity at amino acids 318-510 (RBD, Receptor Binding Domain) in the S1 subunit of the Spike protein.  The native monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.  The ELISA Plate was coated with the target proteins at 5 µg/ml. Primary antibodies were titrated on a 3-fold serial dilution starting at 125 ng/ml,  CoV-2 IgG S1 antibody recognises SARS-CoV-2 spike protein subunit 1 (aa 1-674), or 41.6 ng/ml CoV-2 IgG S1 antibody recognised spike protein from SARS-CoV (subunit 1, aa 1-666) and SARS-CoV-2 (subunit 1, aa 1-674). Secondary antibody anti-human IgG conjugated to HRP used in the assay, at 1:4000 concentration. This product was purified through Protein A affinity and avaiable in the formulation: 1mg/ml in PBS and 0.02% Proclin 300F.